Aurobindo Pharma Acquires Lannett for Rs 2,185 Cr to Boost U.S. Presence, ADHD Line

Financially, Lannett has remained stable, with revenues of $314 million (Rs 2,744 crore) in FY 2023, $286 million (Rs 2,499 crore) in FY 2024, and $306 million (Rs 2,674 crore) for the trailing twelve months of FY 2025.

The acquisition is expected to provide significant operational and cost synergies to Aurobindo. It adds a differentiated and profitable portfolio of controlled substances to Aurobindo’s offerings, and the Seymour facility presents an opportunity for future capacity expansion. Furthermore, the deal allows Aurobindo to capitalize on NCE-1 exclusivity opportunities through Lannett’s late-stage research pipeline and will help lower unit costs through improved efficiency and optimized SG&A functions.

The transaction, however, remains subject to regulatory approvals, including clearance from the U.S. Federal Trade Commission (FTC). It is expected to close within the next 8 to 12 months, depending on the regulatory timeline.

Advisors to Aurobindo on the deal include Sullivan & Cromwell, Khaitan & Co, EY India, Sagene Advisors, KNAV, Ice Miller, USI, and IES Consulting. On the other hand, Lannett was advised by Raymond James & Associates as financial advisor, with Honigman LLP and Dechert LLP serving as legal counsel.